Founded in the 1980s, Biopharm Australia is committed to furthering animal health through the best technology. Biopharm has been a world leader in osteoarthritis treatments for over 30 years. In order to achieve our aim of improving health through improved technology, Biopharm heavily invests in the development of new technologies and medicines that improve the quality of life of animals and strengthens the human-animal bond through good medicine.
Safety has always been at the forefront of our products, particularly with complex and large molecules such as polysaccharides. Of course, efficacy is the cornerstone of our products with clinical studies being carried out in Australia, Canada, Denmark, Finland, Germany, Japan, New Zealand, the United Kingdom and USA. Scientific collaboration has been carried out with numerous local and overseas institutions.
Biopharm Australia
Founded in Australia in the 1980s, Biopharm Australia is a world leader in the research and development of sulfated polysaccharides for use in veterinary medicine and has ongoing research and development commitments in osteoarthritis, musculoskeletal diseases and cancer.
Biopharm Australia pioneered the veterinary development of sodium pentosan polysulfate as a disease modifying osteoarthritis drug (DMOAD) under the brand Cartrophen. The company invests heavily in the research and development of medicines that improve animal quality of life and strengthen the human-animal bond.
Biopharm Australia was incorporated in 1987 in Sydney, Australia. It was established to advance healthy treatments for osteoarthritis.
(* Cartrophen Vet is registered as Anarthron in these countries)